Tissue plasminogen activator-based clot busting: Controlled delivery approaches. by El-Sherbiny, IM et al.
OPEN ACCESS Review article
Tissue plasminogen activator-based
clot busting: Controlled delivery
approaches
Ibrahim M. El-Sherbiny1,*, Islam E. Elkholi2, Magdi H. Yacoub3
ABSTRACT
Cardiovascular diseases are the leading cause of death worldwide. Thrombosis, the formation of blood
clot (thrombus) in the circulatory system obstructing the blood flow, is one of the main causes behind
various ischemic arterial syndromes such as ischemic stroke and myocardial infarction, as well as vein
syndromes such as deep vein thrombosis, and consequently, pulmonary emboli. Several thrombolytic
agents have been developed for treating thrombosis, the most common being tissue plasminogen
activator (tPA), administrated systemically or locally via IV infusion directly proximal to the thrombus,
with the aim of restoring and improving the blood flow. TPA triggers the dissolution of thrombi by
inducing the conversion of plasminogen to protease plasmin followed by fibrin digestion that
eventually leads to clot lysis. Although tPA provides powerful thrombolytic activity, it has many
shortcomings, including poor pharmacokinetic profiles, impairment of the reestablishment of normal
coronary flow, and impairment of hemostasis, leading to life-threatening bleeding consequences. The
bleeding consequence is ascribed to the ability of tPA to circulate throughout the body and therefore
can lysis all blood clots in the circulation system, even the good ones that prevent the bleeding
and promote injury repair. This review provides an overview of the different delivery approaches for
tPA including: liposomes, ultrasound-triggered thrombolysis, anti-fibrin antibody-targeted tPA,
camouflaged-tPA, tpA-loaded microcarriers, and nano-modulated delivery approaches.
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1. INTRODUCTION
Hemostasis is a multifactorial state that ensures efficient blood flow through peripheral vascular
districts. It is affected by the characteristics of blood vessel walls, platelets, the fibrinolytic system, and
the coagulation pathway, which are all intimately related (Figure 1). All these factors function normally
to produce an equilibrium between antithrombotic and prothrombotic factors.1,2 Any misbalance in this
equilibrium will lead to thrombosis: the formation of a blood clot inside a vessel, causing its occlusion
or stenosis, and leading to various clinical presentations, depending on the occluded vessel. For
instance, cerebrovascular thrombosis will lead to stroke and coronary artery thrombosis will lead to
ischemic heart diseases (angina or myocardial infarction).
Thrombosis takes place in two stages, primary hemostasis, and secondary hemostasis (Figure 2).3
Primary hemostasis is initiated by platelets’ adherence to the damaged vascular endothelium, in a
complex involving multiple platelet membrane receptors, to form a platelet plug.4 Secondary
hemostasis includes the activation of the coagulation system, which finally leads to conversion of
fibrinogen into fibrin to form a hemostatic clot.5 Platelet adhesion to the endothelium via the GP Ib
Figure 1. Factors affecting hemostasis.
Figure 2. An illustration of the stages of thrombosis.
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receptor and von Willebrand factor (VWF) is followed by platelet activation (in the form of shape
changes in the platelet, release of thromboxane A2, serotonin and other agents, and expression of
GP IIb/ IIIa receptors on platelets’ surface). The final step is binding of fibrinogen and VWF to the
activated GP IIb/ IIIa receptors of two platelets, creating a growing aggregate.3,6
As the primary and secondary hemostasis phases are dynamically interactive, the plasma
coagulation system is activated at the time of formation of the platelet plug. Coagulation is often been
represented as two independent pathways (extrinsic and intrinsic) that converge into a single
interrelated system or pathway, with thrombin generation as the end point of the cascade.3,7 Thrombin
converts fibrinogen into fibrin, and it also activates factor XIII, leading to stabilization of the fibrin clot.
In addition, it is a potent stimulant of platelet aggregation.8 As a result, thrombin generation is a key
goal in the management of thrombosis.
In spite of the relatively large number of available drugs, tissue plasminogen activator (tPA) is still the
main and the primary thrombolytic agent used in the treatment of established thrombus in myocardial
infarction (MI) and pulmonary embolism.9–11 Tissue plasminogen factor is one of the physiological
plasminogen activators which can be used clinically. This family also includes streptokinase (SK) and
urokinase (UK). These agents catalyze the hydrolysis of plasminogen at the Arg561–Val562 bond,
which results in the formation of active plasmin. The plasmin then acts by degrading the insoluble
fibrin clot, which forms the nucleus of the thrombus.12–14 However, tPA has a short half-life (,5 min),
which necessitates its administration in a large dose (1 mg/kg) to have the desired effect. This can lead
to the degradation of clotting factors and hemorrhage.15,16 Although a lower bolus dose can be used,
followed by prolonged infusion, it is not the ideal manner in which to optimize the benefit of, and
minimize side effects from, tPA.
In order to minimize the risk of bleeding, many strategies have been developed to offer local
thrombolytic action of tPA, or in other words, targeting of tPA. In this review, we are going to discuss the
most common delivery approaches of tPA such as liposomes, ultrasound-triggered thrombolysis, anti-
fibrin antibody-targeted tPA, camouflaged-tPA, tpA-loaded microcarriers, and nano-modulated delivery
approaches.
2. CONTROLLED DELIVERY APPROACHES FOR TPA
2.1. Liposomes
Liposomes are vesicular drug delivery systems that consist of lipid bilayer arrays.17,18 Each lipid layer
consists of two parts, hydrophilic and hydrophobic. The hydrophilic parts are directed towards the
aqueous phase, while the hydrophobic segments are directed towards each other.19 This structure
gives liposomes the opportunity to encapsulate both water-soluble and water-insoluble bioactive
materials.20 Liposomes are highly biocompatible with low immunogenicity,21 and they are also
characterized by their efficient encapsulation of drugs. This separation from external conditions leads
to a decrease in side effects resulting from nonspecific actions, such as bleeding in the case of
plasminogen activators.22
Liposomes have been investigated as a drug delivery system for tPA (Figure 3).23–25 Heeremans and
his team have proved that tPA-loaded liposomes have higher anti-thrombolytic effect as compared to
the free tPA.24 The main drawback of liposomes, however, is their relatively rapid rate of clearance from
the circulatory system, due to phagocytosis by the reticuloendothelial system (RES), resulting in their
short half-life.26
This shortcoming has been overcome via chemical modifications of the surface of the liposome with
substances such as polyethylene glycol (PEG) in a process called PEGylation, leading to a significant
decrease in the uptake of liposomes by RES.27,28
PEG has several advantages, including high water solubility and low cytotoxicity. In addition, the
PEGylated-liposomes or vesicles demonstrate high stability due to steric repulsion, which prevents the
fusion and disruption of the vesicles.29 Moreover, liposomal modification with PEG widens the
applicability of liposomes by enhancing their circulation time, in addition to improving their targeting
capabilities.30
Ji-Young Kim et al. for instance, used PEGylated liposomes to prolong circulation of tPA.25 In their
study, encapsulation of tPA into conventional liposomes (EPCL) and PEGylated-liposomes (EPC-PEGL)
prolonged the half-life of tPA by 16- and 21-fold, respectively, compared with free tPA. The half-life of
free tPA was prolonged from about 5.87 minutes in the terminal phase, to 50.03 min and 132.62 min for
EPCL and EPC-PEGL, respectively.
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In another study,31 Absar and his co-workers encapsulated tPA into PEGylated and non-PEGylated
liposomes decorated with the peptide sequence (CQQHHLGGAKQAGDV) of fibrinogen gamma-chain
that has the affinity to bind with the GPIIb/IIIa receptors expressed on activated platelets. This
decoration enhanced the liposomal affinity to bind with activated platelets. Consequently, the half-life
of tPA has extended from 7 minutes (for free tPA) to 103 and 141 minutes in the case of non-PEGylated
and PEGylated liposomes, respectively.
Another advantage of liposomes is the ability to encapsulate gas and fluid to form an echogenic
liposome (ELIP). These echogenic liposomes have been utilized as ultrasound contrast agents to assist
in ultrasound-enhanced thrombolysis.32
2.2. Ultrasound-enhanced thrombolysis
Ultrasound has been found beneficial in thrombolysis since the 1970s,33,34 and can be used either
alone,35–37 or as the trigger component of a drug delivery system for tPA.38–40
Francis41 has proposed that ultrasound can enhance thrombolysis via two different approaches,
mechanical fragmentation of the clot or by enhancing enzymatic fibrinolysis by increasing the enzyme
transport to thrombus via static42 and perfusion43 systems.
Recently, Everbach and Francis attributed the effect of ultrasound to the growth and/ or collapse of
micro-bubbles within the clot, followed by the occurrence of two pathways. In the first pathway, the
formed bubbles are enlarged and their diameters exceed that of the pores of the fibrin lattice
surrounding them, leading to stretching of the clot fibers. In the other pathway, the bubbles may
collapse in a violent way, producing acoustic emissions and inertial cavitations, and consequently
altering the structure of clot fibers. Both pathways lead to same result; producing new binding sites for
the fibrinolytic enzyme, in addition to a stirring force produced by micro-streaming around the bubbles,
which increases the chance of the fibrinolytic enzyme coming in contact with the fibrin strands.44
This assumption was in agreement the suggestion of Nyborg and Ziskin in 1985, where they
attributed the action of ultrasound to three main mechanisms: acoustic streaming, cavitation and a
thermal effect.45 To explain the process more clearly, Alexandrov stated that “if you put sugar in a water
cup, the sugar promptly goes down to the bottom, and it will take some time for it to dissolve
completely due to absence of water motion. Upon stirring water with a spoon, sugar dissolves much
faster. In a similar fashion, the enzyme spends a long time to reach the goal because of the stagnant
flow near occlusion”.46
In spite of the various advantages of ultrasound, using it alone has some drawbacks. For instance, it
causes vessel wall damage41 and high intensity ultrasound can break the clot into smaller particles,
causing embolization.41,47
In addition, it was discovered, based on both in-vitro48 and in-vivo49 studies, that ultrasound-
induced thrombolysis may cause activation of platelets, leading to re-occlusion. As a result, ultrasound
use has been restricted as a trigger for releasing tPA.
Figure 3. Different investigated types of liposomes-loaded tPA.
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Kudo and his group were the first to report using ultrasound as a non-invasive approach to increase
the efficiency of systemic tPA.50–52 With the aid of a canine model, they found that continuous
application of transcutaneous ultrasound at frequency of 200 kHz enhanced tPA-induced
thrombolysis.50–52 Many subsequent experimental studies, either using ultrasound with tPA alone53,54
or, more recently, in the presence of various contrast agents,39,40,55,56 have shown that ultrasound
increased the efficiency of tPA.
Based on the promising results of these experimental studies,53–56 a number of clinical studies have
been carried out which demonstrated the enhanced efficacy of ultrasound-based thrombolysis in
stroke patients.57–60
Alexandrov and his team used diagnostic ultrasound to improve thrombolysis by tPA.57,58 They used
a 2-MHz transcranial Doppler (TCD) in patients with acute ischemic stroke due to occlusion of middle
cerebral artery (MCA), and the TCD was applied in a continuous manner. They observed that patients
monitored with TCD during clinical-course treatment with systemic tPA revealed early recanalization
and dramatic recovery.57 Afterwards, this observation was tested through a multicenter clinical trial,
CLOTBUST (Combined Lysis of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic
tPA).58 The study involved two groups of patients, each group consisting of 63 patients, where the
target group received continuous ultrasound (tPA þ TCD) and the control group received placebo (tPA
alone). The results showed that 83% of the target group showed recanalization (46% complete and
27% partial) versus 50% (17% complete and 33% partial) for the control group. In addition, 3.8 % of
both groups demonstrated symptomatic intracerebral hemorrhage.58 As a result, it was postulated, by
Alexandrov et al. that continuous monitoring by TCD might have augmented the thrombolytic effect of
tPA by exposing more clot surface to tPA. Exposing more surface of the clot surface was attributed to
pressure gradients formed at the clot site by the ultrasonic energy emitted from TCD, where this
pressure leads to tPA molecules being forced and lodged into the clot.57
In another clinical trial, Eggers et al.60 used diagnostic ultrasound to improve the thrombolytic effect
of tPA. A total of 25 patients were used in the study; a target group of 11 patients received duplex
monitoring and tPA, while the control group, consisting of 14 patients, received tPA alone. The results
showed better recanalization and neurological outcome after 3 months in the target group. However,
the intracerebral hemorrhage rate was higher in the target group. These results were not considered
sufficient to judge the effect of transcranial duplex due to the small number of patients investigated in
the study.60
In another clinical trial using therapeutic low-frequency ultrasound, Daffertshofer et al.61 found that
low-frequency (300 KHz) ultrasound led to a considerable increase in the rate of symptomatic
intracerebral hemorrhage, up to 36%, and consequently, the TRUMBI trial (TRanscranial low-frequency
Ultrasound-Mediated thrombolysis in Brain Ischemia) was terminated. As a conclusion, and
surprisingly, it has been found that lower ultrasound frequencies (in kilohertz) are causing higher rates
of intracerebral hemorrhage,61 while, the diagnostic frequencies (in megahertz) did not and are safe
enough to be used in humans.58,60
For further improvement of ultrasound enhanced-thrombolysis, the concept of using contrast agents
for better imaging and delivery of thrombolytic agents was tested. Micro-bubbles and echogenic
liposomes were two principle examples of these utilized contrast agents.
2.3. Micro-bubbles
Micro-bubbles (MBs) are tiny gas- or air-filled microspheres and were first used as contrast agents for
imaging due to their acoustic characteristics.62–64 In diagnostic ultrasonograpghy, MBs create acoustic
impedance that is higher than that of red blood cells,65 giving them the ability to send stronger echoes
and leading to better reflection. The mechanism by which the MBs enhanced ultrasound-accelerated
thrombolysis was attributed to stable and inertial cavitation as these MBs act as nuclei for cavitation
decreasing the amount of energy required for the cavitation.66,67 Stable cavitation leads to oscillations
of MBs, resulting in micro-streaming, and therefore, erosion of clot surface which enhances the
penetration of the clot by fibrinolytic enzymes.44 Inertial cavitation is induced by increasing the
acoustic power on MBs, leading to an explosion which emits the absorbed energy.68,69 The effect of
MBs on thrombolysis depends on many factors, such as bubble size, concentration of the MBs in the
clot area, and the stability of the bubbles in blood stream.67 Being air-filled and encapsulated by a
weak shell, this leads the first generation of MBs to be cleared rapidly from systemic circulation due to
their low stability. In addition, their relatively large size reduced their ability to cross into lung
Page 340 of 349
El-Sherbiny, Elkholi and Yacoub. Global Cardiology Science and Practice 2014:46
circulation and get into the thrombus.70,71 As a result, a second generation of MBs was introduced by
filling the MBs with a high molecular weight gas in addition to encapsulation of the MBs by
phospholipids72 – galactose in the case of levovist, or thin shell albumin in the case of Albunex.67,68
Before being introduced to the clinical trials, the effect of MBs on enhancing ultrasound-based
thrombolysis was tested by many experimental studies.73–75 In one of these clinical trials, Molina
et al.67 evaluated 111 patients with acute stroke caused by MCA occlusion. Patients were divided into
3 groups. The first group included 38 patients who received tPA plus continuous two-hour TCD
monitoring plus galactose-based MBs (tPA þ US þ MBs). The second group included 37 patients who
received tPA with continuous two-hour TCD monitoring (tPA þ US). Finally, the third group consisted of
36 patients receiving tPA with placebo monitoring (tPA alone). It was found that complete
recanalization was significantly higher in the first group (54.5%) than in the second (40.8%) and third
(23.9%) groups. Furthermore, 2.6 % of the first group, 2.7% of the second, and 5.5% of the third group
showed symptomatic intracranial hemorrhage. These results were in agreement with the results
obtained by Viguier and his group.73
In another pilot study, Alexandrov et al. tested perflutren-lipid microspheres in patients with acute
ischemic stroke.74 Fifteen patients were divided into two groups; target group (12 patients), and a
control group (3 patients). The target group received tPA with perflutren-lipid microspheres in addition
to two-hour continuous TCD monitoring (tPA þ MBs þ TCD), while the control group received tPA with
monitoring by TCD only (tPA þ TCD). The results demonstrated that within 2 hours after tPA bolus,
50% of the target group showed complete recanalization (6/12 patients), and 33% showed partial
recanalization (4/12) while 2 patients showed no recanalization (17%). No patients in the control group
showed complete recanalization.
Both studies by Alexandrov et al.74 and Molina et al.67 are considered as an extension for the
CLOTBUST study,58 introducing the concept of testing contrast agents in the form of MBs. Table 1
summarizes and compares the results of CLOTBUST58 with Molina’s study,67 and Alexandrov’s study.74
The second example of contrast agents is echogenic liposomes (ELIP). Echogenic liposomes are
multifunctional liposomes, phospholipid-bilayer encapsulated vesicles, which can be used as contrast
agents for sonography, and at the same time, as a drug delivery system.19,75
On encapsulating a gas in a liposome, the gas acts as a hydrophobic drug and stays trapped
between the two monolayers of the lipid-bilayer of the liposome.76 The overall entrapment efficiency
tPA into the liposomes was about 50%. Of that 50%, around 35% of the loaded tPA were associated
with the lipid bilayer and only 15% were encapsulated within the liposome.77 Therefore, the term
‘tPA-loaded echogenic liposome’ refers to the total of the tPA associated with the lipid shell, in addition
to the part encapsulated in the aqueous phase.23
The exposure of the liposomes to ultrasound induces the disruption of the lipid shell and hence the
release of the drug.19 As a result, ELIP loaded with tPA (t-ELIP) acts as a targeted drug delivery system
by increasing the concentration of tPA in the area of the thrombus, leading to a decrease in the
required high systemic dose of tPA, and consequently lowers the possibilities of hemorrhage. The gas
encapsulated into t-ELIP will exert a cavitation-related mechanism, as explained earlier, leading to
more lytic effect against the thrombus.78–80 In a study aimed at evaluation of the effect of exposing
tPA-loaded ELIP to ultrasound in thrombolysis, Laing et al. found that ELIP-induced thrombolysis
improved by 49.5% when ultrasound was added to the treatment protocol.77 This was in agreement
with what Shaw and his team found when they compared the thrombolytic efficacy of tPA alone with
that of tPA with ultrasound (120 kHz), and t-ELIP with t-ELIP exposed to ultrasound.81 It was found that
ultrasound enhanced the efficacy of both tPA (from 31% alone to 71% with ultrasound) and t-ELIP (from
48% alone to 89% with ultrasound) and the study confirmed that t-ELIP can be used as an effective
delivery system for tPA.81
In conclusion, contrast agents can enhance ultrasound-induced thrombolysis. Further modifications
of MBs and echogenic liposomes, as well as the trials of targeting MBs82,83 and echogenic liposomes,84
may lead to the introduction of new efficient thrombolytic strategies that could be applied at the
clinical level.
2.4. Anti-fibrin antibody targeting method
One of the main strategies of targeting tPA, or enhancing the local effect of tPA on thrombus, is the use
of anti-fibrin antibody targeting.85,86 Yang and his co-workers designed an approach87–90 and called it
“ATTEMPTS” (Antibody Targeted Triggered Electrically Modified Prodrug Type Strategy). It was designed
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to deliver tPA to the clot site in an inactive form, followed by triggering its activation locally, and
consequently reducing the risk of bleeding.
This system depends on tight reversible electrostatic interaction between the targeting moiety in the
form of an anionic heparin molecule (Hep) conjugated to an anti-fibrin antibody (Ab), and the drug
moiety in the form of a tPA molecule decorated by a cationic peptide.
The antibody plays a vital role in targeting the system to the site of thrombus. The heparin-antibody
conjugate blocks the active site of tPA, inhibiting its anti-fibrinolytic effect. Then, to activate this system,
protamine sulfate is administered as an antagonist for heparin and triggers the dissociation of the Hep-
antibody complex, resulting in the release of tPA from the inhibitory action of this complex.
This approach was tested experimentally in-vitro and in-vivo, and did not elicit any considerable
degradation of the coagulation factors when compared to free tPA.87,91
In 2005, Yang and his group presented a new strategy to overcome the problem of random results of
modification tPA with cationic peptide.90 They used a genetic engineering approach of site-directed
mutagenesis to develop an inherent region with surface expressing positive charges to trigger binding
with heparin.90 This led to a safe strategy for enhancing thrombolysis.
2.5. Camouflaged-tPA delivery approach
In a number of studies,92–94 Absar et al. tried to introduce an efficient delivery system for tPA.
Camouflaged-tPA was produced by conjugating tPA with low molecular weight heparin (LMWH)
followed by complexion of this conjugate with albumin-protamine.92 The administration of heparin
with tPA led to 71% clot lysis, which is more effective than tPA alone (52% clot lysis). However, using
heparin with tPA increased the bleeding risk, which led to a two-fold increase in activated partial
thromboplastin time (aPTT). In a contrary situation, albumin-camouflaged heparin triggered strategy
achieved a similar clot lysis activity (70%) compared to tPA plus heparin administration, but with no
prolongation of aPTT after 1 hour of treatment. This indicates that the camouflaged-tPA can be applied
for targeted thrombolysis with a reduced risk of hemorrhage.92 Based on the fact that LMWH is a
therapeutically active molecule, Absar et al. in another study93, have tested a relatively inert
negatively-charged compound to synthesize oligoanion-modified tPA to avoid any potential side
effects. The tPA was conjugated to polyglutamate, and separately the human serum albumin (HSA) was
conjugated to protamine. The conjugation of tPA with polyglutamate forms a reversible electrostatic
complex that could be disrupted by negatively charged heparin via competitive binding. The
electrostatic complex formation between polyglutamate and protamine can be reversed by heparin
also. It was found that camouflaged-tPA heparin triggered delivery system demonstrated higher activity
than the un-camouflaged tPA, where this higher activity may be attributed to the protection of
camouflaged tPA from its macromolecular inhibitors. In another modification for the camouflaged-tPA
delivery system, Absar and his colleagues94 have conjugated tPA with HSA via a thrombin-cleavable
peptide or linker (GFPRGFPAGGC). In addition, the surface of albumin was decorated by the peptide
sequence (CQQHHLGGAKQAGDV) of fibrinogen gamma-chain that has the affinity to bind with
GPIIb/IIIa receptors, which are expressed on activated platelets. This conjugate showed an activity of
25%, which increased to about 86% of that of native tPA when the conjugate was incubated with
thrombin. This approach can introduce an efficient delivery system for tPA working in an on/off
triggered manner (Figure 4).
2.6. Microcarriers delivery system
Microcarriers (MC) have many advantages, such as offering a large volume for encapsulating drugs,
and the possibility of co-encapsulation of magnetic nanomaterials to facilitate the control of
microspheres against vascular flow.95 Torno and Kaminski compared the lysis effect of free tPA with
that of tPA combined with magnetic microcarriers (MMC), and with that of tPA combined with MMC
upon exposure to external magnetic field (MF). They also examined the lysis effect of tPA combined
with MMC, exposed to both MF and ultrasound (US). They found that under static and no-flow
conditions, thrombolysis efficiency improved by 1.7 and 2.7 fold for red and white clots, respectively in
the case of (tPA þ MMC þ MF). Whereas under flow conditions, they reported a two-fold increase in
lysis with a significant reduction in recanalization time by 7-fold. Furthermore, in the case of
(tPA þ MMC þ MF þ US), a maximal lysis efficiency of almost 98% was achieved for both red and
white clots.96 Later, Kaminski et al.95 developed a new magnetic-targeting delivery system via
encapsulating tPA in magnetic poly (lactic acid)-poly(ethylene glycol) (PLA-PEG) microcarriers.
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They reported that this delivery system has increased the overall activity of tPA by preserving its
concentration up to 74 ug/ml, which is significantly higher than the concentration needed for efficient
clot lysis (1–4 ug/ml).95
2.7. Nano-modulated delivery approaches
One of the first nano-modulated approaches is the use of tPA-loaded magnetic nanoparticles (MNPs).
MNPs offer a good drug delivery system because of their composition and tailorability. MNPs are
usually composed of a core made of iron oxide, Fe3O4, and a polymer coating. The core is responsible
for the supermagnetic characteristics, which can be controlled by applying an external magnetic field,
while the polymer coating is beneficial in increasing the stability and inhibiting the particles
Figure 4. An illustration of the various camouflaged-tPA delivery approaches. Adopted with modification from
Absar et al.92–94
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aggregation.97,98 In addition, being composed of iron oxide, the MNPs demonstrate very limited toxicity
and high biocompatibility making their use safe and popular.99,100
In this context, Maet et al. studied the efficacy of magnetic targeted delivery of recombinant tPA
(r-tPA) in a rat embolic model.101 A blood clot was produced in vitro and then injected into the iliac
artery. Then, a permanent magnet was placed above the left iliac artery in order to manipulate the
MNPs. It was found from the study that the intra-arterial infusion of the r-tPA significantly reversed the
iliac flow within 15 minutes. Moreover, retention of MNPs against the hemodynamic dragging force in
the iliac artery of the rat occurred. On the other hand, the MNPs retention was very limited in the
absence of the magnetic field.
In another study using the same embolic rat model, Ma and his team have developed polyacrylic
acid-coated MNPs to target r-tPA.102,103 Polyacrylic acid (PAA) was used in this study to stabilize MNPs
because it produces electrostatic and steric repulsion preventing the particles aggregation. The study
showed that static magnetic field produced by the external magnet with PAA-MNP-r-tPA didn’t
produce reversal in hemodynamics. On the other hand, applying the magnetic field periodically in an
on/off way did the job, indicating that thrombolysis is achieved by mechanical dragging force
created by movement of MNPs under the effect of external magnetic field. In conclusion, moving the
external magnetic field led to suspension of MNPs and enhancing the penetration of r-tPA into the
thrombus.102
In accordance with Ma’s results,101–103 Chen et al.99 used chitosan coated-MNPs to deliver tPA.
Chitosan is a hydrophilic polysaccharide obtained from chitin which is naturally extracted from the
shells of shrimps and crabs. Chitosan has many beneficial characteristics, such as excellent
biodegradability and low toxicity.104 Chen et al.99 found that clot lysis time was reduced when using
chitosan-MNP-tPA in the presence of an applied external magnetic field by 58% compared to other
runs without magnetic targeting, or by 53% compared to free tPA at the same dose of tPA (0.1mg/ml).
The concept of on/off triggering of thrombolysis has been utilized in several approaches,92–94,102
and a novel ultrasound-responsive nano-delivery system for tPA has been developed.38,105,106
This system is composed of tPA complexed with cationic gelatin and PEG-gelatin. This composition
depends on the electrostatic interaction between tPA, with its negative zeta potential, and a positively
charged cationic gelatin leading to inactivation of tPA. Upon exposure of this composite to ultrasound,
the tPA regains its activity. Upon administration of the delivery system without ultrasound, none of the
animals showed recanalization. In the case of free tPA, however, half of the animals showed
recanalization.38
Uesugi et al. modified this system by adding zinc ions to the complex of tPA and gelatin.105 It was
found that zinc ions modified the resulting complex through coordinate and ionic bonds leading to
greater suppression of tPA activity. Exposing this modified system to ultrasound at 1 MHz and 0.75
W/cm2 for 5 minutes, the system showed a 2-fold increase in tPA activity compared to the original
level.105
Kawata and Uesgui et al. evaluated this modified system in vivo,106 where they found that the plasma
tPA activity, determined immediately after injection of tPA-loaded nanoparticles, was almost 71.4%
lower than after administration of the same dose of free tPA. On the other hand, the activity of
nanoparticles recovered to a similar level to free tPA after being exposed to transcutaneous ultrasound
for 5 minutes.
After 40 minutes the plasma tPA activity produced by nanoparticles after being exposed to
ultrasound reached a level higher than that produced by free tPA.106 This approach gives hope for a
safe drug delivery system for tPA, leading to reducing the risk of bleeding resulting from using high
doses of free tPA.
FUTURE PROSPECTIVE
Nanomedicine potentially opens up novel delivery approaches and new methods of targeting tPA to
decrease the risk of bleeding. Shear-activated nanotherapeutics (SA-NTs) represent one of these novel
approaches in controlled delivery and targeting of tPA.107 The mechanism of SA-NT relies on the fact
that there is difference between normal blood vessels and stenosed or thrombosed one. As a result
SA-NTs can be targeted to the site of thrombus in a size similar to that of platelets. Upon exposure to
high local shear stress, they break up into nanosized particles. In addition, they are safe to be used as
they are rapidly cleared (80% clearance in 5 minutes).107
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Nanomedicine also allows for the development of “stealth” technology in which tPA is encapsulated
in gelatin nanoparticles complexed with zinc ions.38,105,106 This opens up the possibility of developing
protein therapeutics in vascular diseases, another promising field.
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